Results 21 to 30 of about 3,587 (183)

Terlipressin or Europressin? [PDF]

Critical Care, 2009
Use of terlipressin in septic shock relies on a series of European studies resulting in a better knowledge of this vasopressive agent. Additional studies demonstrate that this agent appears to have attractive properties when administered properly.
openaire   +2 more sources

Role of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Admitted to the ICU: A Substudy of the CONFIRM Trial

Critical Care Explorations, 2023
IMPORTANCE AND OBJECTIVES:. This study assessed the potential advantages of treating hepatorenal syndrome-acute kidney injury (HRS-AKI) with terlipressin versus placebo in the ICU setting. DESIGN:.
Constantine J. Karvellas, MD, Ram Subramanian, MD, Jody C. Olson, MD, Khurram Jamil, MD   +3 more
doaj   +1 more source

Challenges in the Treatment of Hepatorenal Syndrome-Acute Kidney Injury: A US Chart Review of Treatment Patterns and Survival Outcomes. [PDF]

JGH Open
ABSTRACT Background Treatments for hepatorenal syndrome with acute kidney injury (HRS‐AKI) that are not FDA‐approved have been widely used in the United States (US) with variable outcomes. This study describes the practice patterns, outcomes, and healthcare utilization around vasopressor use before terlipressin approval in 2022. Methods A retrospective
Sanyal AJ, Reddy KR, Brown KA, Landis CS, Cullaro G, Huang X, Kelkar SS, Raina R, Corman S, Kebede N, Edmundson P, Jamil K, Allegretti AS.   +12 more
europepmc   +2 more sources

Terlipressin [PDF]

Reactions Weekly, 2005
The vasopressing agent terlipressin is a commonly used drug with various indications especially in patients with advanced cirrhosis. Being a potent vasoconstrictor it increases the systemic vascular pressure especially inthe splanchnic area, resulting in a decrease of portal pressure. Due to complex pathophysiologic patterns, different complications of
T. Brünnler, F. Mandraka, J. Langgartner   +2 more
openaire   +2 more sources

Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico

Annals of Hepatology, 2009
Introduction. Type 1 hepatorenal syndrome (HRS) is a functional renal failure that complicates end-stage cirrhosis. The vasopressin analogue terlipressin has been associated with improved renal function in patients with type 1 HRS.Aim.
Linda E. Muñoz, Eliud G. Alcalá, Paula Cordero, Manuel A. Martinez, Nathalie Y. Vázquez, Susana Galindo, Eduardo Mendoza, José J. Segura   +7 more
doaj   +1 more source

Practice guidance for the use of terlipressin for liver cirrhosis–related complications

Therapeutic Advances in Gastroenterology, 2022
Background: Liver cirrhosis is a major global health burden worldwide due to its high risk of morbidity and mortality. Role of terlipressin for the management of liver cirrhosis–related complications has been recognized during recent years.
Xingshun Qi, Zhaohui Bai, Qiang Zhu, Gang Cheng, Yu Chen, Xiaowei Dang, Huiguo Ding, Juqiang Han, Lei Han, Yingli He, Fanpu Ji, Hongxu Jin, Bimin Li, Hongyu Li, Yiling Li, Zhiwei Li, Bang Liu, Fuquan Liu, Lei Liu, Su Lin, Dapeng Ma, Fanping Meng, Ruizhao Qi, Tianshu Ren, Lichun Shao, Shanhong Tang, Yufu Tang, Yue Teng, Chunhui Wang, Ran Wang, Yunhai Wu, Xiangbo Xu, Ling Yang, Jinqiu Yuan, Shanshan Yuan, Yida Yang, Qingchun Zhao, Wei Zhang, Yongping Yang, Xiaozhong Guo, Weifen Xie   +40 more
doaj   +1 more source

Two-component vasopressor therapy for septic shock

Вестник анестезиологии и реаниматологии, 2021
The objective: to investigate the efficacy and safety of terlipressin when it is used as an additional vasopressor in septic shock.Subjects: A single-center, observational, retrospective-prospective study of the efficacy and safety of combined therapy of
A. A. Kochkin, V. V. Likhvantsev, К. К. Kadantseva   +2 more
doaj   +1 more source

The haemodynamic effects of the perioperative terlipressin infusion in living donor liver transplantation: A randomised controlled study

Indian Journal of Anaesthesia, 2015
Background and Aims: Liver disease is usually accompanied with a decline in systemic vascular resistance (SVR). We decided to assess effects of the peri-operative terlipressin infusion on liver donor liver transplantation recipients with respect to ...
Nagwa Ibrahim, Ashraf Hasanin, Sabry Abd Allah, Eman Sayed, Mohamed Afifi, Khaled Yassen, Wesam Saber, Magdy Khalil   +7 more
doaj   +1 more source

Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome [PDF]

Clinical and Molecular Hepatology, 2013
Terlipressin is a vasopressin analogue that is widely used in the treatment of hepatorenal syndrome or variceal bleeding. Because it acts mainly on splanchnic vessels, terlipressin has a lower incidence of severe ischemic complications than does ...
Hae Rim Kim, Young Sun Lee, Hyung Joon Yim, Hyun Joo Lee, Ja Young Ryu, Hyun Jung Lee, Eileen L. Yoon, Sun Jae Lee, Jong Jin Hyun, Sung Woo Jung, Ja Seol Koo, Rok Sun Choung, Sang Woo Lee, Jai Hyun Choi   +13 more
doaj   +1 more source

INFUSE: Rationale and design of a multi-center, open label, collaborative study to treat HRS-AKI with continuous terlipressin infusion

Contemporary Clinical Trials Communications, 2023
Background: Hepatorenal syndrome-acute kidney injury (HRS-AKI) carries significant morbidity and mortality among those with end-stage liver disease. Bolus terlipressin for treatment of HRS-AKI received FDA approval in September 2022. US implementation of
Ethan Weinberg, Suditi Rahematpura, Stevan A. Gonzalez, Manhal J. Izzy, Douglas A. Simonetto, R. Todd Frederick, Raymond A. Rubin, Jade Ikahihifo-Bender, Maggie Harte, Grace Kim-Lee, Sherry Witkiewicz, William Tobin, Khurram Jamil, Zachary Fricker, K. Rajender Reddy   +14 more
doaj   +1 more source